# US 2016/0355891 A1 · Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355891 A1
- Document ID: US20160355891A1
- Status: Published application
- Kind: A1
- Application number: 15/242,011
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2011-08-31
- Assignees: Ventana Medical Systems, Inc.; Arizona Board of Regents on Behalf of the University of Arizona
- Applicants: Ventana Medical Systems, Inc.; The Arizona Board of Regents on behalf of the University of Arizona
- Inventors: Gary Pestano; Ray B. Nagle; Connie Cortez; Kristie A. Vanpatten; Amit M. Algotar
- Web page: https://patentgrep.com/patent/US20160355891A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57555: of the prostate
- G01N 33/57575: {involving oncogenic proteins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.

## Claims

### Claim 1

A kit for predicting the likelihood of prostate cancer progression, comprising:
means for detecting in a biological sample an ERG genomic sequence, ERG transcript or ERG protein;
means for detecting in a biological sample a PTEN genomic sequence, PTEN transcript or PTEN protein; or
any combination of thereof.

### Claim 2 (depends on 1)

The kit of claim 1, wherein the kit comprises:
a means for detecting in a biological sample an ERG transcript or protein; and
a means for detecting in a biological sample a PTEN transcript or protein.

### Claim 3 (depends on 1)

The kit of claim 1, wherein the kit comprises:
a nucleic acid probe specific for ERG transcript and a nucleic acid probe specific for PTEN transcript;
a pair of primers for specific amplification of an ERG transcript and a pair of primers for specific amplification of a PTEN transcript; or
an antibody specific for ERG protein and an antibody specific for a PTEN protein.

### Claim 4 (depends on 3)

The kit of claim 3, wherein the a nucleic acid probe specific for ERG transcript and the nucleic acid probe specific for PTEN transcript each comprise a label.

### Claim 5 (depends on 3)

The kit of claim 3, wherein the pair of primers for specific amplification of an ERG transcript and the pair of primers for specific amplification of a PTEN transcript each comprise a label.

### Claim 6 (depends on 3)

The kit of claim 3, wherein the antibody specific for ERG protein and the antibody specific for a PTEN protein each comprise a label.

### Claim 7 (depends on 4)

The kit of claim 4, wherein the label is a radioactive isotope, fluorophore, chromophore, ligand, chemiluminescent agent, enzyme, or combination thereof.

### Claim 8 (depends on 5)

The kit of claim 5, wherein the label is a radioactive isotope, fluorophore, chromophore, ligand, chemiluminescent agent, enzyme, or combination thereof.

### Claim 9 (depends on 6)

The kit of claim 6, wherein the label is a radioactive isotope, fluorophore, chromophore, ligand, chemiluminescent agent, enzyme, or combination thereof.

### Claim 10 (depends on 1)

The kit of claim 1, wherein the kit comprises at least two detection means selected from the group consisting of:
a nucleic acid probe specific for ERG transcript, a nucleic acid probe specific for PTEN transcript, a pair of primers for specific amplification of ERG transcript, a pair of primers for specific amplification of PTEN transcript, an antibody specific for ERG protein, and an antibody specific for a PTEN protein.

### Claim 11 (depends on 1)

The kit of claim 1, further comprising a detection means selected from the group consisting of:
a nucleic acid probe specific for a control transcript, a pair of primers for specific amplification of a control transcript, and an antibody specific for a control protein.

### Claim 12 (depends on 11)

The kit of claim 11, wherein the control transcript or control protein is β-actin, GAPDH, SDHA, HPRT1, HBS1L, AHSP or a combination thereof.

### Claim 13 (depends on 1)

The kit of claim 1, further comprising a detection means selected from the group consisting of:
a nucleic acid probe specific for a prostate cancer-related gene transcript, a pair of primers for specific amplification of a prostate cancer-related gene transcript, and an antibody specific for a prostate cancer-related protein.

### Claim 14 (depends on 11)

The kit of claim 11, wherein the prostate cancer-related gene transcript or the prostate cancer-related protein is GAS1; WNT5A; TK1; BRAF; ETV4; tumor protein p63; BCL-2; Ki67; ERK5; or PSA.

### Claim 15 (depends on 1)

The kit of claim 1, wherein the means for detecting in a biological sample an ERG genomic sequence, ERG transcript or ERG protein and the means for detecting in a biological sample a PTEN genomic sequence, PTEN transcript or PTEN protein are covalently attached to a solid support.
